

WEST Search History

DATE: Monday, June 23, 2003

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

L10	L4 and binder and lubricant and disintegrant and diluent	10	L10
L9	l5 and lactose-free	8	L9
L8	astemizole	643	L8
L7	L4 and astemizole	55	L7
L6	L4 same astemizole	52	L6
L5	L4 or astemizole	657	L5
L4	norastemizole	69	L4
L3	norastemizol	3	L3
L2	norastemizole and coated same particles	5	L2
L1	norastemizole same coated same particles	2	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 18:22:13 ON 23 JUN 2003)

FILE 'REGISTRY' ENTERED AT 18:22:46 ON 23 JUN 2003

E NORASTEMIZOLE/CN

L1 1 SEA ABB=ON PLU=ON NORASTEMIZOLE/CN
D L1

FILE 'CAPLUS' ENTERED AT 18:23:45 ON 23 JUN 2003

L2 65 SEA ABB=ON PLU=ON L1
L3 12 SEA ABB=ON PLU=ON L1 AND (TABLET OR CAPSULE)
L4 0 SEA ABB=ON PLU=ON L1 (P) (PARTICLE OR PARTICULATE OR
MICROPARTICLE) AND COATED
L5 0 SEA ABB=ON PLU=ON L1 (P) (PARTICLE OR PARTICULATE OR
MICROPARTICLE) AND COATED
D L3 IBIB KWIC 1-
L6 5 SEA ABB=ON PLU=ON (L2 OR L3) AND (MICROCRYSTALLINE CELLULOSE
OR PREGELATINIZED STARCH OR MAGNESIUM STEARATE OR CROSCARMELO
SE SODIUM)
L7 1 SEA ABB=ON PLU=ON (L2 OR L3) AND (MICROCRYSTALLINE CELLULOSE
) AND PREGELATINIZED STARCH AND MAGNESIUM STEARATE AND
CROSCARMELOSE SODIUM
D L7 IBIB
D L6 IBIB KWIC 1-
D L6 IBIB KWIC 1-
L8 57 SEA ABB=ON PLU=ON COATED (P) (TABLET OR CAPSULE) AND
FILM-FORM? (P) (METHYLCELLULOSE OR ETHYLCELLULOSE OR CELLULOSE
DERIVATIVE OR HPMC OR HYDROXYPROPYL METHYL CELLULOSE OR
CARBOXYMETHYLCELLULOSE)
L9 0 SEA ABB=ON PLU=ON L8 AND CROSSLINKED (5A) ETHYLCELLULOSE
L10 57 SEA ABB=ON PLU=ON COATED (P) (TABLET OR CAPSULE) AND
FILM-FORM? (P) (CROSSLINKED (5A) ETHYLCELLULOSE OR METHYLCELLULO
SE OR ETHYLCELLULOSE OR CELLULOSE DERIVATIVE OR HPMC OR
HYDROXYPROPYL METHYL CELLULOSE OR CARBOXYMETHYLCELLULOSE)
L11 1 SEA ABB=ON PLU=ON L10 AND (NORASTEMIZOLE OR BENZIMIDAZOLE)
D L11 IBIB KWIC 1-
L12 2 SEA ABB=ON PLU=ON BENZIMIDAZOLE (P) NORASTEMIZOLE
D L12 IBIB KWIC 1-

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:558680 CAPLUS
DOCUMENT NUMBER: 113:158680
TITLE: Oral preparation of an acid-unstable compound
INVENTOR(S): Saeki, Yasuharu; Koyama, Noritoshi; Watanabe, Sumio;
Aoki, Shigeru
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 342522	A1	19891123	EP 1989-108492	19890511
EP 342522	B1	19911218		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 01290628	A2	19891122	JP 1988-121233	19880518
JP 07068125	B4	19950726		
US 5035899	A	19910730	US 1989-332731	19890404
FI 8901650	A	19891119	FI 1989-1650	19890406
FI 93422	B	19941230		
FI 93422	C	19950410		
CA 1336958	A1	19950912	CA 1989-598474	19890502
AT 70442	E	19920115	AT 1989-108492	19890511
ES 2051919	T3	19940701	ES 1989-108492	19890511
NO 8901935	A	19891120	NO 1989-1935	19890512
NO 178135	B	19951023		
NO 178135	C	19960131		
DD 283771	A5	19901024	DD 1989-328639	19890516
DK 8902391	A	19891119	DK 1989-2391	19890517
HU 51896	A2	19900628	HU 1989-2461	19890517
HU 203200	B	19910628		

PRIORITY APPLN. INFO.: JP 1988-121233 19880518
EP 1989-108492 19890511

AB An oral prepn. of an acid-unstable compd. comprises a core contg. the unstable compd., a 1st layer, **coated** on the core, comprising a hardly water-sol., **film-forming** material and fine particles of a hardly water-sol. compd., suspended in the material; and a 2nd layer, **coated** on the 1st layer of enteric film. Thus an acid-unstable compd. (I), mannitol, MgO, and hydroxypropyl cellulose (HPC) were granulated, and mixed with a granulation contg. cellulose, starch, and HPC along with CM-cellulose, talc, and Mg stearate and tableted. The **tablets** were **coated** with am EtOH soln. contg. Et cellulose with silicic anhydride dispersed in the soln. Finally, the intermediated-**coated tablets** were **coated** with a 80% EtOH-H2O soln. contg. **hydroxypropyl Me cellulose** phthalate, TiO2, talc, and Myvacet 9-40T to give enteric **coated tablets**.

ST tablet enteric acid unstable drug; **benzimidazole** drug acid unstable tablet

IT Phärmaceuticā dosage forms
(**tablets**, enteric-**coated**, for acid unstable drugs)

6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:124005 CAPLUS

DOCUMENT NUMBER: 128:208908

TITLE: Treatment of upper airway allergic responses with a combination of histamine receptor antagonists

INVENTOR(S): Kreutner, William; Hey, John A.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806394	A1	19980219	WO 1997-US13903	19970813
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
ZA 9707263	A	19980216	ZA 1997-7263	19970813
AU 9739733	A1	19980306	AU 1997-39733	19970813
AU 722040	B2	20000720		
EP 920315	A1	19990609	EP 1997-937153	19970813
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO			
BR 9711149	A	19990817	BR 1997-11149	19970813
CN 1233179	A	19991027	CN 1997-198713	19970813
JP 2000505094	T2	20000425	JP 1998-509859	19970813
NZ 334063	A	20000929	NZ 1997-334063	19970813
JP 2003095979	A2	20030403	JP 2002-222138	19970813
KR 2000029975	A	20000525	KR 1999-701226	19990212
NO 9900706	A	19990215	NO 1999-706	19990215
PRIORITY APPLN. INFO.:			US 1996-689951 A	19960816
			JP 1998-509859 A3	19970813
			WO 1997-US13903 W	19970813

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amt. of a histamine H1 receptor antagonist; together with (b) a sufficient amt. of a histamine H3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or sep. in the same or different dosage forms to maintain therapeutic systemic levels of both components. The nasal airways resistance following injection of 3 mg/kg loratadine and 10 mg/kg thioperamide in cats was 2.1 as compared with 10.2 for loratadine alone. A **tablet** contained H1 antagonist effective amt., H3 antagonist effective amt., lactose 100, 10% corn starch past 5, dried corn starch 25, and **magnesium stearate** 1.25 mg.

ST upper airway allergy histamine receptor antagonist; loratadine thioperamide nasal decongestant **tablet**

IT Drug delivery systems

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**capsules**; treatment of upper airway allergic responses with combination of histamine receptor antagonists)

IT Drug delivery systems

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tablets; treatment of upper airway allergic responses with combination of histamine receptor antagonists)

IT 58-73-1, Diphenhydramine 59-33-6 60-87-7, Promethazine 68-88-2, Hydroxyzine 82-92-8, Cyclizine 84-96-8, Trimeprazine 86-22-6, 91-81-6, Tripeleennamine 113-92-8 129-03-3, Cyproheptadine 486-12-4, Triprolidine 486-16-8, Carbinoxamine 523-87-5, Dimenhydrinate 562-10-7 569-65-3, Meclizine 3964-81-6, Azatadine 5636-83-9, Dimethindene 5786-21-0, Clozapine 14838-15-4, Phenylpropanolamine 15686-51-8, Clemastine 24219-97-4, Mianserin 29216-28-2, Mequitazine 34580-13-7, Ketotifen 34970-69-9, Burimamide 39577-19-0, Picumast 46129-28-6, Skf-91486 50679-08-8, Terfenadine 55273-05-7, Impromidine 58581-89-8, Azelastine 68844-77-9, Astemizole 75970-99-9, Norastemizole 79313-75-0, Sopromidine 79516-68-0, Levocabastine 79794-75-5, Loratadine 80012-43-7, EPinastine 83184-43-4, Mifentidine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 86181-42-2, Temelastine 87848-99-5, Acrivastine 90729-42-3, Carebastine 90729-43-4, Ebastine 99616-14-5, S-Sopromidine 100643-71-8, Descarboethoxyloratadine 106243-16-7, Thioperamide 108612-45-9, Mizolastine 110588-56-2, Noberastine 145231-45-4, Clobenpropit 150036-88-7, Verongamine 150756-35-7, Efletirizine 152030-16-5, UCL 1199 152241-24-2, Gt-2016 176860-26-7, GR 175737

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of upper airway allergic responses with combination of histamine receptor antagonists)

=> d his full

(FILE 'HOME' ENTERED AT 18:22:13 ON 23 JUN 2003)

FILE 'REGISTRY' ENTERED AT 18:22:46 ON 23 JUN 2003

E NORASTEMIZOLE/CN

L1 1 SEA ABB=ON PLU=ON NORASTEMIZOLE/CN
D L1

FILE 'CAPLUS' ENTERED AT 18:23:45 ON 23 JUN 2003

L2 65 SEA ABB=ON PLU=ON L1
L3 12 SEA ABB=ON PLU=ON L1 AND (TABLET OR CAPSULE)
L4 0 SEA ABB=ON PLU=ON L1 (P) (PARTICLE OR PARTICULATE OR MICROPARTICLE) AND COATED
L5 0 SEA ABB=ON PLU=ON L1 (P) (PARTICLE OR PARTICULATE OR MICROPARTICLE) AND COATED
D L3 IBIB KWIC 1-
L6 5 SEA ABB=ON PLU=ON (L2 OR L3) AND (MICROCRYSTALLINE CELLULOSE OR PREGELATINIZED STARCH OR MAGNESIUM STEARATE OR CROSCARMELOSE SODIUM)
L7 1 SEA ABB=ON PLU=ON (L2 OR L3) AND (MICROCRYSTALLINE CELLULOSE) AND PREGELATINIZED STARCH AND MAGNESIUM STEARATE AND CROSCARMELOSE SODIUM
D L7 IBIB
D L6 IBIB KWIC 1-
D L6 IBIB KWIC 1-

> d l3 ibib kwic l-
YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:202410 CAPLUS
DOCUMENT NUMBER: 138:226705
TITLE: Novel pharmaceuticals comprising drug conjugates with
polypeptide carriers
INVENTOR(S): Picariello, Thomas
PATENT ASSIGNEE(S): New River Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 2059 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020200	A2	20030313	WO 2001-US43117	20011116
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2000-248600P	P 20001116
			US 2000-248601P	P 20001116
			US 2000-248603P	P 20001116
			US 2000-248604P	P 20001116
			US 2000-248606P	P 20001116
			US 2000-248607P	P 20001116
			US 2000-248608P	P 20001116
			US 2000-248609P	P 20001116
			US 2000-248611P	P 20001116
			US 2000-248689P	P 20001116
			US 2000-248691P	P 20001116
			US 2000-248692P	P 20001116
			US 2000-248693P	P 20001116
			US 2000-248694P	P 20001116
			US 2000-248695P	P 20001116
			US 2000-248696P	P 20001116
			US 2000-248697P	P 20001116
			US 2000-248698P	P 20001116
			US 2000-248701P	P 20001116
			US 2000-248702P	P 20001116
			US 2000-248703P	P 20001116
			US 2000-248704P	P 20001116
			US 2000-248705P	P 20001116
			US 2000-248706P	P 20001116
			US 2000-248707P	P 20001116
			US 2000-248708P	P 20001116
			US 2000-248709P	P 20001116
			US 2000-248710P	P 20001116
			US 2000-248711P	P 20001116
			US 2000-248712P	P 20001116

IT Drug delivery systems
(tablets; novel pharmaceuticals comprising drug conjugates
with polypeptide carriers)
IT 50-06-6D, Phenobarbital, polypeptide conjugates 50-35-1D, Thalidomide,

polypeptide conjugates 50-81-7D, Vitamin c, polypeptide conjugates 51-21-8D, Fluorouracil, polypeptide conjugates 51-48-9D, Levothyroxine, polypeptide conjugates 52-01-7D, Spironolactone, polypeptide conjugates 52-24-4D, Thiotepa, polypeptide conjugates 52-53-9D, Verapamil, polypeptide conjugates 53-03-2D, Prednisone, polypeptide conjugates 55-63-0D, Nitroglycerin, polypeptide conjugates 57-27-2D, Morphine, polypeptide conjugates 57-41-0D, Phenytoin, polypeptide conjugates 57-63-6D, Ethinyl estradiol, polypeptide conjugates 58-55-9D, Theophylline, polypeptide conjugates 58-93-5D, Hydrochlorothiazide, polypeptide conjugates 60-54-8D, Tetracycline, polypeptide conjugates 60-87-7D, Promethazine, polypeptide conjugates 67-20-9D, Nitrofurantoin, polypeptide conjugates 68-19-9D, Vitamin b12, polypeptide conjugates 68-22-4D, Norethindrone, polypeptide conjugates 71-58-9D, Medroxyprogesterone acetate, polypeptide conjugates 72-69-5D, Nortriptyline, polypeptide conjugates 74-79-3D, Arginine, polypeptide conjugates 76-42-6D, Oxycodone, polypeptide conjugates 76-57-3D, Codeine, polypeptide conjugates 81-81-2D, Warfarin, polypeptide conjugates 83-43-2D, Methylprednisolone, polypeptide conjugates 84-02-6D, Prochlorperazine maleate, polypeptide conjugates 87-08-1D, Penicillin v, polypeptide conjugates 89-57-6D, Mesalamine, polypeptide conjugates 90-82-4D, Pseudoephedrine, polypeptide conjugates 99-66-1D, Valproic acid, polypeptide conjugates 103-90-2D, Acetaminophen, polypeptide conjugates 113-45-1D, Methylphenidate, polypeptide conjugates 114-07-8D, Erythromycin, polypeptide conjugates 125-33-7D, Primidone, polypeptide conjugates 128-13-2D, Ursodiol, polypeptide conjugates 396-01-0D, Triamterene, polypeptide conjugates 443-48-1D, Metronidazole, polypeptide conjugates 469-62-5D, Propoxyphene, polypeptide conjugates 525-66-6D, Propranolol, polypeptide conjugates 541-15-1D, Levocarnitine, polypeptide conjugates 554-13-2D, Lithium carbonate, polypeptide conjugates 595-33-5D, Megestrol acetate, polypeptide conjugates 604-75-1D, Oxazepam, polypeptide conjugates 657-24-9D, Metformin, polypeptide conjugates 846-49-1D, Lorazepam, polypeptide conjugates 846-50-4D, Temazepam, polypeptide conjugates 1247-42-3D, Methylprednisone, polypeptide conjugates 1404-90-6D, Vancomycin, polypeptide conjugates 1508-65-2D, Oxybutynin chloride, polypeptide conjugates 1665-48-1D, Metaxalone, polypeptide conjugates 1744-22-5D, Riluzole, polypeptide conjugates 2078-54-8D, Propofol, polypeptide conjugates 2152-34-3D, Pemoline, polypeptide conjugates 3056-17-5D, Stavudine, polypeptide conjugates 3930-20-9D, Sotalol, polypeptide conjugates 4682-36-4D, Orphenadrine citrate, polypeptide conjugates 6493-05-6D, Pentoxifylline, polypeptide conjugates 6893-02-3D, Triiodothyronine, polypeptide conjugates 9002-69-1D, Relaxin, polypeptide conjugates 9004-10-8D, Insulin, polypeptide conjugates 9005-49-6D, Heparin, polypeptide conjugates 9014-42-0D, Thrombopoietin, polypeptide conjugates 9039-53-6D, Urokinase, polypeptide conjugates 10118-90-8D, Minocycline, polypeptide conjugates 10540-29-1D, Tamoxifen, polypeptide conjugates 11056-06-7D, Bleomycin, polypeptide conjugates 13392-28-4D, Rimantadine, polypeptide conjugates 14611-51-9D, Selegiline, polypeptide conjugates 17560-51-9D, Metolazone, polypeptide conjugates 19767-45-4D, Mesna, polypeptide conjugates 19794-93-5D, Trazodone, polypeptide conjugates 21256-18-8D, Oxaprozin, polypeptide conjugates 21829-25-4D, Nifedipine, polypeptide conjugates 22204-53-1D, Naproxen, polypeptide conjugates 23031-32-5D, Terbutaline sulfate, polypeptide conjugates 27203-92-5D, Tramadol, polypeptide conjugates 27314-97-2D, Tirapazamine, polypeptide conjugates 30516-87-1D, Zidovudine, polypeptide conjugates 31441-78-8D, Mercaptopurine, polypeptide conjugates 33069-62-4D, Paclitaxel, polypeptide conjugates 36791-04-5D, Ribavirin, polypeptide conjugates 37300-21-3D, Pentosan polysulfate, polypeptide conjugates 40391-99-9D, polypeptide conjugates 42200-33-9D, Nadolol, polypeptide conjugates 42924-53-8D, Nabumetone, polypeptide conjugates 49842-07-1D, Tobramycin sulfate, polypeptide conjugates 50700-72-6D, Vecuronium, polypeptide conjugates 50851-57-5D, polypeptide conjugates 51321-79-0D, Sparfosic

acid, polypeptide conjugates 51322-75-9D, Tizanidine, polypeptide conjugates 51384-51-1D, Metoprolol, polypeptide conjugates 52232-67-4D, Teriparatide, polypeptide conjugates 52757-95-6D, Sevelamer, polypeptide conjugates 53179-11-6D, Loperamide, polypeptide conjugates 53230-10-7D, Mefloquine, polypeptide conjugates 54024-22-5D, Desogestrel, polypeptide conjugates 54182-58-0D, Sucralfate, polypeptide conjugates 55142-85-3D, Ticlopidine, polypeptide conjugates 56211-40-6D, Torsemide, polypeptide conjugates 59122-46-2D, Misoprostol, polypeptide conjugates 61477-96-1D, Piperacillin, polypeptide conjugates 61512-21-8D, Thymosin, polypeptide conjugates 61869-08-7D, Paroxetine, polypeptide conjugates 63590-64-7D, Terazosin, polypeptide conjugates 63675-72-9D, Nisoldipine, polypeptide conjugates 65271-80-9D, Mitoxantrone, polypeptide conjugates 65807-02-5D, Goserelin, polypeptide conjugates 66085-59-4D, Nimodipine, polypeptide conjugates 66104-22-1D, Pergolide, polypeptide conjugates 66357-35-5D, Ranitidine, polypeptide conjugates 68562-41-4D, Mecasermin, polypeptide conjugates 68693-11-8D, Modafinil, polypeptide conjugates 70458-96-7D, Norfloxacin, polypeptide conjugates 73590-58-6D, Omeprazole, polypeptide conjugates 74381-53-6D, Leuprolide acetate, polypeptide conjugates 75330-75-5D, Lovastatin, polypeptide conjugates 75970-99-9D, Norastemizole, polypeptide conjugates 76470-66-1D, Loracarbef, polypeptide conjugates 76547-98-3D, Lisinopril, polypeptide conjugates 76963-41-2D, Nizatidine, polypeptide conjugates 79517-01-4D, Octreotide acetate, polypeptide conjugates 79617-96-2D, Sertraline, polypeptide conjugates 79794-75-5D, Loratidine, polypeptide conjugates 79902-63-9D, Simvastatin, polypeptide conjugates 81093-37-0D, Pravastatin, polypeptide conjugates 81627-83-0D, Mscf, polypeptide conjugates 82419-36-1D, Ofloxacin, polypeptide conjugates 82626-48-0D, Zolpidem, polypeptide conjugates 82657-92-9D, Prourokinase, polypeptide conjugates 83015-26-3D, Tomoxetine, polypeptide conjugates 83200-96-8D, Carbapenem, polypeptide conjugates 83366-66-9D, Nefazodone, polypeptide conjugates 83799-24-0D, Fexofenadine, polypeptide conjugates 84449-90-1D, Raloxifene, polypeptide conjugates 85441-61-8D, Quinapril, polypeptide conjugates 85650-52-8D, Mirtazapine, polypeptide conjugates 87333-19-5D, Ramipril, polypeptide conjugates 87679-37-6D, Trandolapril, polypeptide conjugates 90566-53-3D, Fluticasone, polypeptide conjugates 91161-71-6D, Terbinafine, polypeptide conjugates 91374-21-9D, Ropinirole, polypeptide conjugates 91421-42-0D, Rubitecan, polypeptide conjugates 93413-69-5D, Venlafaxine, polypeptide conjugates 95635-55-5D, Ranolazine, polypeptide conjugates 96036-03-2D, Meropenem, polypeptide conjugates 96829-58-2D, Orlistat, polypeptide conjugates 97240-79-4D, Topiramate, polypeptide conjugates 97322-87-7D, Troglitazone, polypeptide conjugates 99614-02-5D, Ondansetron, polypeptide conjugates 100286-97-3D, Milrinone lactate, polypeptide conjugates 100986-85-4D, Levofloxacin, polypeptide conjugates 103475-41-8D, Tepoxalin, polypeptide conjugates 103628-46-2D, Sumatriptan, polypeptide conjugates 103775-10-6D, Moexipril, polypeptide conjugates 104632-26-0D, Pramipexole, polypeptide conjugates 106133-20-4D, Tamsulosin, polypeptide conjugates 106266-06-2D, Risperidone, polypeptide conjugates 106392-12-5D, Poloxamer 188, polypeptide conjugates 106650-56-0D, Sibutramine, polypeptide conjugates 107753-78-6D, Zafirlukast, polypeptide conjugates 109768-33-4D, Sulfx, polypeptide conjugates 111025-46-8D, Pioglitazone, polypeptide conjugates 111974-72-2D, Quetiapine fumarate, polypeptide conjugates 112733-06-9D, Zenarestat, polypeptide conjugates 114798-26-4D, Losartan, polypeptide conjugates 114977-28-5D, Docetaxel, polypeptide conjugates 115103-54-3D, Tiagabine, polypeptide conjugates 117976-89-3D, Rabeprazole, polypeptide conjugates 121032-29-9D, Nelarabine, polypeptide conjugates 121584-18-7D, Valspodar, polypeptide conjugates 121679-13-8D, Naratriptan, polypeptide conjugates 123774-72-1D, Sargramostim, polypeptide conjugates 123948-87-8D, Topotecan, polypeptide conjugates 124584-08-3D, Nesiritide, polypeptide conjugates 124832-26-4D, Valacyclovir, polypeptide conjugates 124937-51-5D,

Tolterodine, polypeptide conjugates 125317-39-7D, Vinorelbine tartrate, polypeptide conjugates 127254-12-0D, Sitafloracin, polypeptide conjugates 127779-20-8D, Saquinavir, polypeptide conjugates 128298-28-2D, Remacemide, polypeptide conjugates 128794-94-5D, Mycophenolate mofetil, polypeptide conjugates 129580-63-8D, Satraplatin, polypeptide conjugates 129618-40-2D, Nevirapine, polypeptide conjugates 130018-77-8D, Levocetirizine, polypeptide conjugates 131918-61-1D, Paricalcitol, polypeptide conjugates 132539-06-1D, Olanzapine, polypeptide conjugates 133737-32-3D, Pagoclone, polypeptide conjugates 133814-19-4D, Mivacurium, polypeptide conjugates 135062-02-1D, Repaglinide, polypeptide conjugates 135354-02-8D, Xaliproden, polypeptide conjugates 137234-62-9D, Voriconazole, polypeptide conjugates 137281-23-3D, Pemetrexed, polypeptide conjugates 137862-53-4D, Valsartan, polypeptide conjugates 138531-07-4D, Sinapultide, polypeptide conjugates 138660-96-5D, Sevirumab, polypeptide conjugates 139264-17-8D, Zolmitriptan, polypeptide conjugates 139639-23-9D, Tissue plasminogen activator, analogs, polypeptide conjugates 143558-00-3D, Rocuronium, polypeptide conjugates 144494-65-5D, Tirofiban, polypeptide conjugates 144980-29-0D, Repinotan, polypeptide conjugates 145202-66-0D, Rizatriptan benzoate, polypeptide conjugates 145375-43-5D, Mitiglinide, polypeptide conjugates 145941-26-0D, Oprelvekin, polypeptide conjugates 147059-75-4D, Trovafloxacin mesylate, polypeptide conjugates 148553-50-8D, Pregabalin, polypeptide conjugates 148883-56-1D, Tifacogin, polypeptide conjugates 151319-34-5D, Zaleplon, polypeptide conjugates 153168-05-9D, Pleconaril, polypeptide conjugates 154039-60-8D, Marimastat, polypeptide conjugates 155141-29-0D, Rosiglitazone maleate, polypeptide conjugates 155213-67-5D, Ritonavir, polypeptide conjugates 158966-92-8D, Montelukast, polypeptide conjugates 159989-65-8D, Nelfinavir mesylate, polypeptide conjugates 162011-90-7D, Rofecoxib, polypeptide conjugates 166089-32-3D, Lintuzumab, polypeptide conjugates 171228-49-2D, Posaconazole, polypeptide conjugates 171599-83-0D, Sildenafil citrate, polypeptide conjugates 180288-69-1D, Trastuzumab, polypeptide conjugates 181695-72-7D, Valdecocixib, polypeptide conjugates 188039-54-5D, Palivizumab, polypeptide conjugates 192329-42-3D, Prinomastat, polypeptide conjugates 193079-69-5D, Tabimorelin, polypeptide conjugates 201341-05-1D, Tenofovir disoproxil, polypeptide conjugates

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel pharmaceuticals comprising drug conjugates with polypeptide carriers)

L3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:889557 CAPLUS

DOCUMENT NUMBER: 137:375287

TITLE: Pharmaceutical compositions comprising norastemizole

INVENTOR(S): Redmon, Martin P.; Butler, Hal T.; Wald, Stephen A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 719,843, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002173522	A1	20021121	US 2002-75616	20020215
WO 9842379	A2	19981001	WO 1998-US5701	19980325
WO 9842379	A3	20010301		

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR,

TT, UA, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

ZA 9802562 A 19981001 ZA 1998-2562 19980326
PRIORITY APPLN. INFO.: US 1997-824477 B2 19970326
US 1997-824477 B2 19970326
US 1997-851786 B2 19970506
US 1997-851786 B2 19970506
WO 1998-US5701 W 19980325
US 2000-719843 B2 20001121
US 2000-721711 B2 20001127

IT Drug delivery systems
(**capsules**; pharmaceutical compns. comprising norastemizole)
IT **75970-99-9**, Norastemizole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising norastemizole)

L3 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:566682 CAPLUS
DOCUMENT NUMBER: 135:142257
TITLE: Single-dose antihistamine/decongestant formulations
for treating rhinitis
INVENTOR(S): Weinstein, Robert E.; Weinstein, Allan M.
PATENT ASSIGNEE(S): J-Med Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S.
Ser. No. 550,761.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001011102	A1	20010802	US 2001-757852	20010110
US 6521254	B2	20030218		
US 6051585	A	20000418	US 1998-206713	19981207
PRIORITY APPLN. INFO.:			US 1998-206713	A2 19981207
			US 2000-550761	A2 20000417

IT Drug delivery systems
(**tablets**, controlled-release; single-dose
antihistamine/decongestant formulations for treating rhinitis)
IT 90-82-4, Pseudoephedrine 14838-15-4, Phenylpropanolamine 68844-77-9,
Astemizole **75970-99-9**, NorAstemizole 79794-75-5, Loratadine
83799-24-0, Fexofenadine 83881-51-0, Cetirizine 100643-71-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(single-dose antihistamine/decongestant formulations for treating
rhinitis)

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:525909 CAPLUS
DOCUMENT NUMBER: 135:111997
TITLE: Osmotic device containing pseudoephedrine and an H1
antagonist
INVENTOR(S): Faour, Joaquina; Ricci, Marcelo A.
PATENT ASSIGNEE(S): Laboratorios Phoenix U.S.A., Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051038	A1	20010719	WO 2001-US528	20010108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002102305	A1	20020801	US 2000-725655	20001129
EP 1246612	A1	20021009	EP 2001-900942	20010108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001007596	A	20021119	BR 2001-7596	20010108
PRIORITY APPLN. INFO.:			US 2000-175878P	P 20000113
			US 2000-725655	A 20001129
			WO 2001-US528	W 20010108

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention provides an osmotic device contg. controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, esp. fexofenadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetd. release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations. Thus, **tablets** contained pseudoephedrine-HCl 24.00, osmagent 7-90, diluent 30-40, binder 40-60, plasticizer 0.5-5, glidant 0.5-5, and lubricant 5-10 mg in the core, cellulose ester, plasticizer, water-sol. polymer, filler, colorant, fexofenadine-HCl in the coating formulation.

IT Drug delivery systems

(tablets, osmotic release; osmotic device contg. pseudoephedrine and H1 antagonist)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 56-81-5, Glycerin, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 60-87-7, Promethazine 63-42-3, Lactose 69-65-8, Mannitol 77-92-9D, Citric acid, esters 80-62-6, Methyl methacrylate 90-82-4, Pseudoephedrine 97-64-3, Ethyl lactate 102-76-1, Triacetin 109-43-3, Dibutyl sebacate 138-22-7, Butyl lactate 321-97-1, D-Pseudoephedrine 471-34-1, Calcium carbonate, biological studies 623-50-7, Ethyl glycolate 670-40-6, D-Pseudoephedrine hydrochloride 7440-23-5D, Sodium, compds., biological studies 7440-70-2D, Calcium, compds., biological studies 7647-14-5, Sodium chloride, biological studies 7757-93-9, Dibasic calcium phosphate 9000-30-0, Guar gum 9002-89-5, Poly(vinyl alcohol) 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Sodium carboxymethyl cellulose 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, esters or ethers, biological studies 9004-35-7, Cellulose acetate 9004-38-0, Cellulose acetate phthalate 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9063-38-1, Sodium starch glycolate 13463-67-7, Titanium oxide, biological studies 14807-96-6, Talc, biological studies 24937-78-8,

Poly(ethylene-vinyl acetate) 25086-89-9 25322-68-3, Poly(ethylene glycol) 25322-69-4, Poly(propylene glycol) 39301-46-7, Calcium pectinate 50679-08-8, Terfenadine 58581-89-8, Azelastine .68844-77-9, Astemizole 75970-99-9, Norastemizole 79794-75-5, Loratadine 80012-43-7, Epinastine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 87848-99-5, ACrivastine 90729-43-4, Ebastine 106392-12-5, Poloxamer 108612-45-9, Mizolastine 108929-04-0 151137-53-0
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (osmotic device contg. pseudoephedrine and H1 antagonist)

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:875749 CAPLUS

DOCUMENT NUMBER: 134:33001

TITLE: Alkali metal and alkaline-earth metal salts of acetaminophen

INVENTOR(S): Ohannesian, Lena A.; Nadig, David; Higgins, John D., III; Rey, Max; Martellucci, Stephen A.

PATENT ASSIGNEE(S): McNeill-PPC, Inc., USA

SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 987,210, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 6160020	A	20001212	US 1998-100284	19980619
------------	---	----------	----------------	----------

WO 9966919	A1	19991229	WO 1999-US13064	19990609
------------	----	----------	-----------------	----------

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9943380	A1	20000110	AU 1999-43380	19990609
------------	----	----------	---------------	----------

PRIORITY APPLN. INFO.: US 1996-771176 B2 19961220

US 1997-987210 B2 19971209

US 1998-100284 A 19980619

WO 1999-US13064 W 19990609

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Isolated salts of acetaminophen are disclosed. Alkali metal and alk.-earth metal salts of acetaminophen are formed by reacting the free acid of acetaminophen with the corresponding metal hydroxide and then immediately isolating the resulting salt. These salts have been found to be more water sol. and less bitter in taste than the free acid form of acetaminophen. The isolated salts may also be combined with other active ingredients. A **tablet** contained calcium acetaminophen 368.23, chlorpheniramine maleate 2, microcryst. cellulose 520.77, silica 4.5, and Mg stearate 4.5 mg.

ST ~~acetaminophen metal salt prepn tablet; tablet-calcium~~
 acetaminophen chlorpheniramine maleate

IT Drug delivery systems
 (tablets; oral compns. contg. acetaminophen metal salt and other actives)

IT 50-78-2, Acetyl salicylic acid 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 53-86-1, Indomethacin 58-08-2, Caffeine, biological studies 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 59-33-6, Pyrilamine 59-42-7, Phenylephrine 60-87-7,

Promethazine 68-88-2, Hydroxyzine 73-31-4, Melatonin 76-42-6, Oxycodone 76-57-3, Codeine 77-09-8, Phenolphthalein 77-19-0, Dicyclomine 77-22-5, Caramiphen 77-23-6, Carbetapentane 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 91-81-6, Tripeleminamine 93-14-1, Guaifenesin 104-31-4, Benzonatate; 113-92-8 125-29-1, Hydrocodone 125-71-3, Dextromethorphan 128-62-1, Noscapine 129-03-3, Cyproheptadine 132-21-8, Dexbrompheniramine 299-42-3, Ephedrine; 317-34-0, Aminophylline 364-62-5, Metoclopramide 466-99-9, Hydromorphone 471-34-1, Calcium carbonate, biological studies 486-12-4, Triprolidine 554-10-9, 3-Iodo-1,2-propanediol 562-10-7, Doxylamine 586-06-1, Metaproterenol 606-04-2, Pamabrom. 616-91-1 642-72-8, Benzydamine 791-35-5, Chlophedianol 915-30-0, Diphenoxylate 2451-01-6, Terpin hydrate 3572-43-8, Bromhexine 3964-81-6, Azatadine 5104-49-4, Flurbiprofen 7020-55-5, Clidinium 7683-59-2, Isoprenaline 8050-81-5, Simethicone 12125-02-9, Ammonium chloride, biological studies 14838-15-4, Phenylpropanolamine 14882-18-9, Bismuth subsalicylate 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 16958-94-4 18053-31-1, Fominoben 18559-94-9, Albuterol; 18683-91-5, Ambroxol 21645-51-2, Aluminum hydroxide, biological studies 22071-15-4, Ketoprofen 22204-53-1, Naproxen 23031-25-6, Terbutaline 25523-97-1, Dexchlorpheniramine 27203-92-5, Tramadol 29679-58-1, Fenoprofen 29975-16-4, Estazolam 30392-40-6, Bitolterol 33005-95-7, Tiaprofenic acid 34580-13-7, Ketotifen 35719-43-8 36322-90-4, Piroxicam 36950-96-6, Cicloprofen 38194-50-2, Sulindac 41340-25-4, Etodolac 42924-53-8, Nabumetone 50679-08-8, Terfenadine 51481-61-9, Cimetidine 51803-78-2, Nimesulide 53179-11-6, Loperamide; 53716-49-7, Carprofen 54182-58-0, Sucralfate 57644-54-9, Bismuth subcitrate 61869-07-6, Domiodol 66357-35-5, Ranitidine 68844-77-9, Astemizole 71125-38-7, Meloxicam 73590-58-6, Omeprazole 74103-06-3, Ketorolac 74978-16-8, Magaldrate 75970-99-9, Norastemizole 76824-35-6, Famotidine 76963-41-2, Nizatidine 79794-75-5, Loratidine 80937-31-1, Flosulide 81098-60-4, Cisapride 82626-48-0, Zolpidem 83799-24-0, Fexofenadine; 83881-51-0, Cetirizine 86181-42-2, Temelastine 87848-99-5, Acrivastine 169590-42-5, Celecoxib 180200-68-4 209967-48-6 209967-50-0 209967-51-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral compns. contg. acetaminophen metal salt and other actives)

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:819235 CAPLUS

DOCUMENT NUMBER: 132:54898

TITLE: Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient

INVENTOR(S): Ohannesian, Lena A.; Nadig, David; Higgins, John D., III; Rey, Max; Martellucci, Stephen A.

PATENT ASSIGNEE(S): Mcneil-PPC, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966919	A1	19991229	WO 1999-US13064	19990609
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6160020 A 20001212 US 1998-100284 19980619

AU 9943380 A1 20000110 AU 1999-43380 19990609

PRIORITY APPLN. INFO.: US 1998-100284 A 19980619

US 1996-771176 B2 19961220

US 1997-987210 B2 19971209

WO 1999-US13064 W 19990609

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB This invention relates to pharmaceutical compns. comprising an alkali or
alk.-earth metal salt of acetaminophen and at least one other active
ingredient selected from the group consisting of analgesics,
decongestants, expectorants, antitussives, antihistamines,
gastrointestinal agents, diuretics, bronchodilators and mixts. thereof.
The acetaminophen salts have both improved aq. soly. and a less bitter
taste than the free acid form of acetaminophen. A **tablet**
contained acetaminophen calcium salt 368.23, chlorpheniramine maleate 2,
microcryst. cellulose 520.77, Cab-O-Sil M5 4.5, and Mg stearate 4.5 mg.

ST **tablet** acetaminophen salt drug combination

IT Drug delivery systems

(tablets; pharmaceutical compns. contg. acetaminophen salts
and other drugs)

IT 50-78-2, Acetylsalicylic acid 51-43-4, Epinephrine 51-55-8, Atropine,
biological studies 53-86-1, Indomethacin 58-08-2, Caffeine, biological
studies 58-55-9, Theophylline, biological studies 58-73-1,
Diphenhydramine 59-33-6, Pyrilamine 59-42-7, Phenylephrine 60-87-7,
Promethazine 68-88-2, Hydroxyzine 73-31-4 76-42-6, Oxycodone
76-57-3, Codeine 77-09-8, Phenolphthalein 77-19-0, Dicyclomine
77-22-5, Caramiphen 77-23-6, Carbetapentane 86-22-6, Brompheniramine
90-82-4, Pseudoephedrine 91-81-6, Tripeleminamine 93-14-1, Guaifenesin
103-90-2 104-31-4, Benzonatate 113-92-8, Chlorpheniramine maleate
125-29-1, Hydrocodone 125-69-9, Dextromethorphan hydrobromide
125-71-3, Dextromethorphan 128-62-1, Noscapine 129-03-3,
Cyproheptadine 132-21-8, Dexbrompheniramine 147-24-0, Diphenhydramine
hydrochloride 299-42-3, Ephedrine 317-34-0, Aminophylline 345-78-8,
Pseudoephedrine hydrochloride 364-62-5, Metoclopramide 466-99-9,
Hydromorphone 471-34-1, Calcium carbonate, biological studies
486-12-4, Triprolidine 554-10-9, 3-Iodo-1,2-propanediol 562-10-7,
Doxylamine 586-06-1, Metaproterenol 606-04-2, Pamabrom 616-91-1,
N-Acetylcysteine 642-72-8, Benzydamine 791-35-5, Chlophedianol
915-30-0, Diphenoxylate 2451-01-6, Terpin hydrate 3572-43-8,
Bromhexine 3964-81-6, Azatadine 5104-49-4, Flurbiprofen 7020-55-5,
Clidinium 7683-59-2, Isoprenaline 8024-48-4, Casanthranol 8050-81-5,
Simethicone 12125-02-9, Ammonium chloride, biological studies
14838-15-4, Phenylpropanolamine 14882-18-9, Bismuth subsalicylate
15307-86-5, Diclofenac 15687-27-1 16958-94-4 18053-31-1, Fominoben
18559-94-9, Albuterol 18683-91-5, Ambroxol 21645-51-2, Aluminum
hydroxide (Al(OH)₃), biological studies 22071-15-4, Ketoprofen
22204-53-1, Naproxen 23031-25-6, Terbutaline 25523-97-1,
Dexchlorpheniramine 27203-92-5, Tramadol 29679-58-1, Fenoprofen
29975-16-4, Estazolam 30392-40-6, Bitolterol 33005-95-7, Tiaprofenic
acid 34580-13-7, Ketotifen 35719-43-8 36322-90-4, Piroxicam
36950-96-6, Cicloprofen 38194-50-2, Sulindac 41340-25-4, Etodolac
42924-53-8, Nabumetone 50679-08-8, Terfenadine 51481-61-9, Cimetidine
51803-78-2 53179-11-6, Loperamide 53716-49-7, Carprofen 57644-54-9,
Bismuth subcitrate 61869-07-6, Domiodol 66357-35-5, Ranitidine
68844-77-9, Astemizole 71125-38-7, Meloxicam 73590-58-6, Omeprazole
74103-06-3, Ketorolac 74978-16-8, Magaldrate **75970-99-9**,
Norastemizole 76824-35-6, Famotidine 76963-41-2, Nizatidine
79794-75-5, Loratidine 80937-31-1, Flosulide 82626-48-0, Zolpidem
83799-24-0, Fexofenadine 83881-51-0, Cetirizine 86181-42-2,

Temelastine 87848-99-5, Acrivastine 169590-42-5, Celecoxib
180200-68-4 209967-47-5 209967-48-6 209967-50-0 209967-51-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(pharmaceutical compns. contg. acetaminophen salts and other drugs)

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:425758 CAPLUS

DOCUMENT NUMBER: 131:63456

TITLE: Composition for treating respiratory and skin
diseases, comprising at least one leukotriene
antagonist and at least one antihistamine

INVENTOR(S): Jensen, Peder K.; Lorber, Richard R.; Danzig, Melvyn
R.; Medeiros, Paul T.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE			
WO 9932125	A1	19990701	WO 1998-US26223	19981221			
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
ZA 9811731	A	19990621	ZA 1998-11731	19981221			
CA 2315721	AA	19990701	CA 1998-2315721	19981221			
AU 9919071	A1	19990712	AU 1999-19071	19981221			
AU 758771	B2	20030327					
BR 9814417	A	20001010	BR 1998-14417	19981221			
EP 1041990	A1	20001011	EP 1998-963828	19981221			
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO						
JP 2001526232	T2	20011218	JP 2000-525116	19981221			
NO 2000003288	A	20000822	NO 2000-3288	20000622			
PRIORITY APPLN. INFO.:			US 1997-68638P	P 19971223			
			US 1998-78638P	P 19980319			
			WO 1998-US26223	W 19981221			
REFERENCE COUNT:	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT					
ST	capsule leukotriene antagonist antihistamine; respiratory skin disease leukotriene antagonist antihistamine						
IT	Drug delivery systems (capsules; compn. for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine)						
IT	Drug delivery systems (tablets; compn. for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine)						
IT	90-82-4, Pseudoephedrine 93-14-1, Guaifenesin 125-71-3, Dextromethorphan 68844-77-9, Astemizole 75970-99-9, Norastemizole 80012-43-7, Epinastine 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 90729-43-4, Ebastine 100643-71-8 103177-37-3,						

Pranlukast 107753-78-6, Zafirlukast 149413-74-1 150756-35-7,
Efletirizine 152952-65-3 158966-92-8, Montelukast 172927-32-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compn. for treating respiratory and skin diseases, comprising at least
one leukotriene antagonist and at least one antihistamine)

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:104511 CAPLUS
DOCUMENT NUMBER: 130:163188
TITLE: Treatment of upper airway allergic responses with H1-
and H3-histamine receptor antagonists
INVENTOR(S): Kreutner, William; Hey, John A.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5869479	A	19990209	US 1997-909319	19970814
PRIORITY APPLN. INFO.:			US 1997-909319	19970814
REFERENCE COUNT:	16	THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

IT Drug delivery systems
(**capsules**; H1- and H3-histamine receptor antagonists for
treatment of rhinitis)

IT Drug delivery systems
(**tablets**; H1- and H3-histamine receptor antagonists for
treatment of rhinitis)

IT 58-73-1, Diphenhydramine 59-33-6 60-87-7, Promethazine 68-88-2,
Hydroxyzine 82-92-8, Cyclizine 84-96-8, Trimeprazine 86-22-6,
Brompheniramine 91-81-6, Tripeleennamine 113-92-8, Chlorpheniramine
maleate 129-03-3, Cyproheptadine 486-12-4, Triprolidine 486-16-8,
Carbinoxamine 523-87-5, Dimenhydrinate 562-10-7 569-65-3, Meclizine
3964-81-6, Azatadine 5636-83-9, Dimethindene 5786-21-0, Clozapine
15686-51-8, Clemastine 24219-97-4, Mianserin 29216-28-2, Mequitazine
34580-13-7, Ketotifen 34970-69-9, Burimamide 34973-91-6, Impentamine
39577-19-0, Picumast 46129-28-6, SKF-91486 50679-08-8, Terfenadine
55273-05-7, Impromidine 58581-89-8, Azelastine 68844-77-9, Astemizole
75970-99-9, Norastemizole 79313-75-0, Sopromidine 79516-68-0,
Levocabastine 79794-75-5, Loratadine 80012-43-7, Epinastine
83184-43-4, Mifentidine 83799-24-0, Fexofenadine 83881-51-0,
Cetirizine 86181-42-2, Temelastine 87848-99-5, Acrivastine
90729-42-3, Carebastine 90729-43-4, Ebastine 99616-14-5, S-Sopromidine
100643-71-8, Descarboethoxyloratadine 106243-16-7, Thioperamide
108612-45-9, Mizolastine 110588-56-2, Noberastine 145231-45-4,
Clobenpropit 148440-81-7 150756-35-7, Efletirizine 152241-24-2,
GT-2016 176860-26-7, GR 175737
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

~~----- (H1- and H3-histamine receptor antagonists for treatment of rhinitis) -----~~

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:672493 CAPLUS
DOCUMENT NUMBER: 129:281025
TITLE: Chemically and thermally stable norastemizole
formulations
INVENTOR(S): Redmon, Martin P.; Butler, Hal T.; Wald, Stephen A.
PATENT ASSIGNEE(S): Sepracor Inc., USA

SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842379	A2	19981001	WO 1998-US5701	19980325
WO 9842379	A3	20010301		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868680	A1	19981020	AU 1998-68680	19980325
AU 735257	B2	20010705		
BR 9808428	A	20000523	BR 1998-8428	19980325
EP 1035869	A1	20000920	EP 1998-914283	19980325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512614	T2	20020423	JP 1998-545893	19980325
ZA 9802562	A	19981001	ZA 1998-2562	19980326
NO 9904655	A	19991115	NO 1999-4655	19990924
US 2002173522	A1	20021121	US 2002-75616	20020215
PRIORITY APPLN. INFO.:			US 1997-824477	A2 19970326
			US 1997-851786	A2 19970506
			WO 1998-US5701	W 19980325
			US 2000-719843	B2 20001121
			US 2000-721711	B2 20001127
AB	The present invention relates to chem. and thermally stable pharmaceutical formulations of the potent antihistamine, norastemizole (I). The compns. are lactose-free, non-hygroscopic, or anhyd., or comprise large particles or inertly coated I, or a pharmaceutically acceptable salt thereof, and are stable and easily manufd. A capsule compn. was prepd. contg. I 2.5, microcryst. cellulose 90.0, pregelatinized starch 100.3, croscarmellose 7.0, and Mg stearate 0.2 mg/ capsule .			
IT	Drug delivery systems (capsules ; chem. and thermally stable norastemizole formulations)			
IT	Drug delivery systems (tablets ; chem. and thermally stable norastemizole formulations)			
IT	75970-99-9 , Norastemizole RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (chem. and thermally stable norastemizole formulations)			

L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:124005 CAPLUS

DOCUMENT NUMBER: 128:208908

~~TITLE: Treatment of upper airway allergic responses with a combination of histamine receptor antagonists~~

INVENTOR(S): Kreutner, William; Hey, John A.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806394	A1	19980219	WO 1997-US13903	19970813
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9707263	A	19980216	ZA 1997-7263	19970813
AU 9739733	A1	19980306	AU 1997-39733	19970813
AU 722040	B2	20000720		
EP 920315	A1	19990609	EP 1997-937153	19970813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
BR 9711149	A	19990817	BR 1997-11149	19970813
CN 1233179	A	19991027	CN 1997-198713	19970813
JP 2000505094	T2	20000425	JP 1998-509859	19970813
NZ 334063	A	20000929	NZ 1997-334063	19970813
JP 2003095979	A2	20030403	JP 2002-222138	19970813
KR 2000029975	A	20000525	KR 1999-701226	19990212
NO 9900706	A	19990215	NO 1999-706	19990215

PRIORITY APPLN. INFO.:

US ~~1996-689951~~ A 19960816
 JP ~~1998-509859~~ A3 19970813
 WO 1997-US13903 W 19970813

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amt. of a histamine H1 receptor antagonist; together with (b) a sufficient amt. of a histamine H3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or sep. in the same or different dosage forms to maintain therapeutic systemic levels of both components. The nasal airways resistance following injection of 3 mg/kg loratadine and 10 mg/kg thioperamide in cats was 2.1 as compared with 10.2 for loratadine alone. A **tablet** contained H1 antagonist effective amt., H3 antagonist effective amt., lactose 100, 10% corn starch past 5, dried corn starch 25, and magnesium stearate 1.25 mg.

ST upper airway allergy histamine receptor antagonist; loratadine thioperamide nasal decongestant **tablet**

IT Drug delivery systems

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**capsules**; treatment of upper airway allergic responses with combination of histamine receptor antagonists)

IT Drug delivery systems

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**tablets**; treatment of upper airway allergic responses with combination of histamine receptor antagonists)

IT 58-73-1, Diphenhydramine 59-33-6 60-87-7, Promethazine 68-88-2, Hydroxyzine 82-92-8, Cyclizine 84-96-8, Trimeprazine 86-22-6 91-81-6, Tripeleennamine 113-92-8 129-03-3, Cyproheptadine 486-12-4, Triprolidine 486-16-8, Carbinoxamine 523-87-5, Dimenhydrinate 562-10-7 569-65-3, Meclizine 3964-81-6, Azatadine 5636-83-9, Dimethindene 5786-21-0, Clozapine 14838-15-4, Phenylpropanolamine 15686-51-8, Clemastine 24219-97-4, Mianserin 29216-28-2, Mequitazine 34580-13-7, Ketotifen 34970-69-9, Burimamide 39577-19-0, Picumast

46129-28-6, Skf-91486 50679-08-8, Terfenadine 55273-05-7, Impromidine
 58581-89-8, Azelastine 68844-77-9, Astemizole 75970-99-9,
 Norastemizole 79313-75-0, Sopromidine 79516-68-0, Levocabastine
 79794-75-5, Loratadine 80012-43-7, EPinastine 83184-43-4, Mifentidine
 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 86181-42-2,
 Temelastine 87848-99-5, Acrivastine 90729-42-3, Carebastine
 90729-43-4, Ebastine 99616-14-5, S-Sopromidine 100643-71-8,
 Descarboethoxyloratadine 106243-16-7, Thioperamide 108612-45-9,
 Mizolastine 110588-56-2, Noberastine 145231-45-4, Clobenpropit
 150036-88-7, Verongamine 150756-35-7, Efletirizine 152030-16-5, UCL
 1199 152241-24-2, Gt-2016 176860-26-7, GR 175737

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of upper airway allergic responses with combination of histamine receptor antagonists)

L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:315821 CAPLUS

DOCUMENT NUMBER: 120:315821

TITLE: Use of norastemizole for the treatment of allergic disorders

INVENTOR(S): Woosley, Raymond L.; Aberg, A. K. Gunnar

PATENT ASSIGNEE(S): Sepracor Inc., USA; Georgetown University

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407495	A1	19940414	WO 1993-US8349	19930903
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 658110	A1	19950621	EP 1993-921359	19930903
EP 658110	B1	19991215		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
GB 2285219	A1	19950705	GB 1995-4329	19930903
GB 2285219	B2	19960911		
DE 4394931	T	19950720	DE 1993-4394931	19930903
JP 08501083	T2	19960206	JP 1993-505651	19930903
AU 687746	B2	19980305	AU 1993-48480	19930903
AU 9348480	A1	19940426		
EP 920865	A1	19990609	EP 1999-200247	19930903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 187642	E	20000115	AT 1993-921359	19930903
ES 2139673	T3	20000216	ES 1993-921359	19930903
JP 2002255817	A2	20020911	JP 2002-54842	19930903
JP 2002308772	A2	20021023	JP 2002-54838	19930903
EP 1262183	A1	20021204	EP 2002-13842	19930903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 6130233	A	20001010	US 1994-182685	19940118
US 6124320	A	20000926	US 1996-766094	19961216
AU 9869884	A1	19980723	AU 1998-69884	19980604
AU 730229	B2	20010301		
US 6187794	B1	20010213	US 2000-481439	20000112
US 6187795	B1	20010213	US 2000-551613	20000417
US 6268382	B1	20010731	US 2000-650645	20000830

US 6303632	B1	20011016	US 2001-835149	20010416
US 2001053787	A1	20011220		
US 6384054	B1	20020507	US 2001-956003	20010920
US 2002137768	A1	20020926	US 2002-108294	20020328
US 6458809	B2	20021001		

PRIORITY APPLN. INFO.:

US 1992-940054	A	19920903
EP 1993-921359	A3	19930903
EP 1999-200247	A3	19930903
JP 1994-505651	A3	19930903
WO 1993-US8349	W	19930903
US 1994-182685	A1	19940118
US 1996-766094	A3	19961216
US 2000-481439	A3	20000112
US 2000-551613	A1	20000417
US 2000-650645	A1	20000830
US 2001-835149	A1	20010416
US 2001-956003	A1	20010920

AB A pharmaceutical compn. comprises norastemizole or a pharmaceutically acceptable salt for use in an antihistaminic treatment which does not induce any significant cardiac arrhythmia. Norastemizole was up to 100 .times. more potent than astemizole as an antihistaminic and 10-20 .times. less potent in causing the serious arrhythmogenic side effect known to be assocd. with astemizole and thus has a therapeutic index 1000-2000 .times. higher than the therapeutic index of the parent compd. **Capsule** and **tablet** formulations are described.

IT Pharmaceutical dosage forms
(**capsules**, of antihistaminic norastemizole, for treatment of allergic disorders)

IT Pharmaceutical dosage forms
(**tablets**, of antihistaminic norastemizole, for treatment of allergic disorders)

IT **75970-99-9**, Norastemizole
RL: BIOL (Biological study)
(as antihistaminic for treatment of allergic disorders)

L3 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1984:432761 CAPLUS

DOCUMENT NUMBER: 101:32761

TITLE: The pharmacokinetics and metabolism of astemizole in man

AUTHOR(S): Heykants, J.

CORPORATE SOURCE: Dep. Drug Metab. Pharmacokinet., Janssen Pharm., Beerse, Belg.

SOURCE: Medicine Publishing Foundation Symposium Series (1984), 11(Astemizole: New Non-Sedat. Long-Acting H1-Antagonist), 25-34
CODEN: MPFSDF; ISSN: 0260-0242

DOCUMENT TYPE: Journal

LANGUAGE: English

IT Digestive tract
(astemizole absorption by, from **tablet** or suspension, in humans)

IT 68844-77-9

RL: BIOL (Biological study)
(bioavailability and pharmacokinetics of, in humans, from **tablet** or suspension)

IT 104-01-8 28030-12-8 73736-50-2 **75970-99-9** 90836-16-1
90836-17-2 90836-18-3 90836-19-4

RL: FORM (Formation, nonpreparative)
(formation of, as astemizole metabolite, in humans)

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:22:46 ON 23 JUN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JUN 2003 HIGHEST RN 535920-83-3
 DICTIONARY FILE UPDATES: 22 JUN 2003 HIGHEST RN 535920-83-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
 PROPERTIES for more information. See STNote 27, Searching Properties
 in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

```
=> e norastemizole/cn
E1      1      NORASPERENAL C/CN
E2      1      NORASPERENAL D/CN
E3      1  --> NORASTEMIZOLE/CN
E4      1      NORASTEMIZOLE HYDROBROMIDE/CN
E5      1      NORASTEMIZOLE HYDROCHLORIDE/CN
E6      1      NORATHEROSPERMININE/CN
E7      1      NORATHYRIOL/CN
E8      1      NORATHYRIOL TETRABENZOATE/CN
E9      1      NORATHYRIOL TETRACINNAMATE/CN
E10     1      NORATHYRIOL TETRACROTONATE/CN
E11     1      NORATHYRIOL TETRANICOTINATE/CN
E12     1      NORATHYRIOL TETRAPALMITATE/CN
```

```
=> d e3
NO L# DEFINED
```

```
=> s e3
L1      1 NORASTEMIZOLE/CN
```


```
=> d l1
```

```
L1      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2003 ACS
RN      75970-99-9  REGISTRY
CN      1H-Benzimidazol-2-amine, 1-[(4-fluorophenyl)methyl]-N-4-piperidinyl- (9CI)
------(CA INDEX NAME)-----
```

OTHER NAMES:

```
CN      1-(4-Fluorobenzyl)-2-(4-piperidylamino)benzimidazole
CN      1-(4-Fluorophenylmethyl)-2-(4-piperidylamino)benzimidazole
CN      Norastemizole
CN      Soltara
CN      T 1348
CN      Tecastemizole
MF      C19 H21 F N4
CI      COM
```

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CEN, CIN, CSCHEM, DDFU, DRUGNL,
DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, PHAR, PROMT,
SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

65 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
65 REFERENCES IN FILE CAPLUS (1957 TO DATE)